Statsols | nQuery

Statsols | nQuery is an Irish company that aims to optimize trial design in clinical trials. The company provides the complete trial design platform, nQuery, which has been in the market for over 20 years. nQuery covers all phases of trials and all types of trial designs, catering to the needs of biostatisticians and researchers worldwide. In 2021, 88% of organizations with FDA approved clinical trials utilized nQuery for their study designs, showcasing its widespread adoption and credibility in the industry.

In 2022, Statsols became part of Dotmatics, a leader in R&D scientific software. Dotmatics is supported by Insight Partners, a prominent venture capital and private equity firm investing in high-growth technology and software scaleup companies. This acquisition marks a significant milestone for Statsols, aligning it with a company trusted by more than 2 million scientists and 10,000 customers to drive efficiency and accelerate innovation in the scientific community.

Statsols boasts an impressive customer base, with a presence in over 100 countries and over 50,000 registered software users45 of the top 50 Pharma companies are Statsols customers, indicating its strong foothold in the pharmaceutical industry. These figures underscore the company's global reach and influence within the market.

Overall, Statsols | nQuery stands out as a prominent player in the field of clinical trial design, with a strong track record of industry adoption and a strategic partnership with Dotmatics, backed by Insight Partners. The company's global presence and significant client base position it as an attractive prospect for potential investment within the technology and software scaleup sector.